Who is sponsoring NCT07432529?

NCT07432529 is sponsored by Azienda Sanitaria Locale ASL 6, Livorno.

What drugs are being tested in NCT07432529?

Interventions in NCT07432529: Colchicine 0.5 MG Oral Tablet, Placebo.

What condition does NCT07432529 study?

NCT07432529 studies Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome, Venous Thromboembolism (VTE), Venous Insufficiency.

Is NCT07432529 still recruiting?

NCT07432529 is currently not yet recruiting. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT07432529: COLT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Design and Rationale of the COLT Study

Not yet recruiting Phase 3 Last updated 25 February 2026

What this trial tests

Phase 3 trial testing Colchicine 0.5 MG Oral Tablet in Venous Thrombosis Deep (Limbs) in 940 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
1 June 2027

1 June 2027

Quick facts

Lead sponsor	Azienda Sanitaria Locale ASL 6, Livorno
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	940
Start date	1 June 2026
Primary completion	1 June 2027
Estimated completion	1 June 2027

Drugs / interventions tested

Colchicine 0.5 MG Oral Tablet
Placebo

Conditions studied

Venous Thrombosis Deep (Limbs) — all drugs for Venous Thrombosis Deep (Limbs) →
Post-thrombotic Syndrome — all drugs for Post-thrombotic Syndrome →
Venous Thromboembolism (VTE) — all drugs for Venous Thromboembolism (VTE) →
Venous Insufficiency — all drugs for Venous Insufficiency →

Sponsor

Azienda Sanitaria Locale ASL 6, Livorno

Who can join

18 and older, any sex, with Venous Thrombosis Deep (Limbs) or Post-thrombotic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Deep vein thrombosis (DVT) is a condition in which a blood clot forms in the deep veins of the leg and can lead to long-term problems such as leg pain, swelling, and reduced quality of life. Standard treatment with blood-thinning medication lowers the risk of complications, but some patients still develop long-term damage to the veins. Inflammation is thought to play an important role in these complications. This study will evaluate whether adding colchicine, an anti-inflammatory medication already used for other conditions, to standard anticoagulant therapy can improve outcomes in patients with acute DVT. Participants will be randomly assigned to receive either colchicine or a placebo, in addition to usual blood-thinning treatment, and will be followed for one year. The main goal of the study is to determine whether colchicine reduces the risk of developing long-term vein problems after DVT. The study will also assess the risk of new blood clots, vein recovery, quality of life, and the safety of colchicine treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Colchicine 0.5 MG Oral Tablet

Trials testing the same drug.

NCT06847204 — EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A · Phase 1, PHASE2 · completed
NCT06095765 — Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention · Phase 3 · recruiting
NCT05949281 — Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes · Phase 2 · active not recruiting
NCT05739929 — Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT) · Phase 3 · unknown
NCT06426537 — Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07432529 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Sanitaria Locale ASL 6, Livorno
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07432529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing